Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 740968, 7 pages
http://dx.doi.org/10.1155/2010/740968
Review Article

Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma

Department of Pathology, Vancouver General Hospital, University of British Columbia, Vancouver 1st Floor JPPN, 855 West 12th Ave, Vanouver, BC, Canada V5Z 1M9

Received 10 July 2009; Accepted 16 September 2009

Academic Editor: Maurie M. Markman

Copyright © 2010 C. Blake Gilks. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. A. Tavassoli and P. Devilee, Eds., World Health Organization Classification of Tumors: Pathology and Genetics. Tumours of the Breast and Female Genital Organs, IARC Press, Lyon, France, 2003.
  2. C. B. Gilks and J. Prat, “Ovarian carcinoma pathology and genetics: recent advances,” Human Pathology, vol. 40, no. 9, pp. 1213–1223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Köbel, S. Kalloger, D. G. Huntsman et al., “Differences in tumor type in low versus high stage ovarian carcinomas,” submitted.
  4. M. Köbel, D. G. Hunstman, and C. B. Gilks, “Critical molecular abnormalities in high-grade serous carcinoma of the ovary,” Expert Reviews in Molecular Medicine, vol. 10, no. e22, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Z. Press, A. de Luca, N. Boyd et al., “Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities,” BMC Cancer, vol. 8, article 17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Farmer, H. McCabe, C. J. Lord et al., “Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy,” Nature, vol. 434, no. 7035, pp. 917–921, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. N. J. Tutt, C. J. Lord, N. McCabe et al., “Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 70, pp. 139–148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. G. D. Girnun, E. Naseri, S. B. Vafai et al., “Synergy between PPAR? ligands and platinum-based drugs in cancer,” Cancer Cell, vol. 11, no. 5, pp. 395–406, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. L. Trimble, J. Fountain, and M. J. Birrer, “Recommendations of the 2005 Ovarian Cancer State of the Science Meeting,” Gynecologic Oncology, vol. 103, no. 2, p. S26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. C. B. Gilks, D. N. Ionescu, S. E. Kalloger et al., “Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma,” Human Pathology, vol. 39, no. 8, pp. 1239–1251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Al-Hussaini, A. Stockman, H. Foster, and W. G. McCluggage, “WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma,” Histopathology, vol. 46, p. 468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Obata, S. J. Morland, R. H. Watson et al., “Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors,” Cancer Research, vol. 58, no. 10, pp. 2095–2097, 1998. View at Google Scholar · View at Scopus
  13. J. Palacios and C. Gamallo, “Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas,” Cancer Research, vol. 58, no. 7, pp. 1344–1347, 1998. View at Google Scholar · View at Scopus
  14. L. Catasús, E. Bussaglia, I. Rodríguez et al., “Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of ß-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas,” Human Pathology, vol. 35, no. 11, pp. 1360–1368, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. S. Falkenberry, M. M. Steinhoff, M. Gordinier et al., “Synchronous endometrioid tumors of the ovary and endometrium: a clinicopathologic study of 22 cases,” Journal of Reproductive Medicine, vol. 41, no. 10, pp. 713–718, 1996. View at Google Scholar · View at Scopus
  16. J. A. Irving, L. Catasús, A. Gallardo et al., “Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the ß-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis,” Human Pathology, vol. 36, no. 6, pp. 605–619, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Sugiyama, T. Kamura, J. Kigawa et al., “Clinical characteristics of clear cell carcinoma of the ovary,” Cancer, vol. 88, no. 11, pp. 2584–2589, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. D. R. Crotzer, C. C. Sun, R. L. Coleman et al., “Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary,” Gynecologic Oncology, vol. 105, no. 2, pp. 404–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. B. A. Goff, D. L. C. Sainz, H. G. Muntz et al., “Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease,” Gynecologic Oncology, vol. 60, no. 3, pp. 412–417, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Pectasides, G. Fountzilas, G. Aravantinos et al., “Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience,” Gynecologic Oncology, vol. 102, no. 2, pp. 285–291, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Sugiyama, T. Kamura, J. Kigawa et al., “Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy,” Cancer, vol. 88, no. 11, pp. 2584–2589, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Itamochi, J. Kigawa, T. Sugiyama et al., “Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary,” Obstetrics and Gynecology, vol. 100, no. 2, pp. 281–287, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Köbel, S. E. Kalloger, N. Boyd et al., “Ovarian carcinoma subtypes are different diseases: implications for biomarker studies,” PLoS Medicine, vol. 5, no. 12, pp. 1749–1760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Köbel, S. E. Kalloger, J. Carrick et al., “A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary,” American Journal of Surgical Pathology, vol. 33, no. 1, pp. 14–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. V. Bokhman, “Two pathogenetic types of endometrial carcinoma,” Gynecologic Oncology, vol. 15, no. 1, pp. 10–17, 1983. View at Google Scholar · View at Scopus
  26. K. K. Zorn, T. Bonome, L. Gangi et al., “Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer,” Clinical Cancer Research, vol. 11, no. 18, pp. 6422–6430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Nagai, M. Inamine, M. Hirakawa et al., “Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary,” Gynecologic Oncology, vol. 107, no. 3, pp. 469–473, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Cuatrecasas, A. Villanueva, X. Matias-Guiu, and J. Prat, “K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases,” Cancer, vol. 79, no. 8, pp. 1581–1586, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. Bookman, K. M. Darcy, D. Clarke-Pearson et al., “Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group,” Journal of Clinical Oncology, vol. 21, no. 2, pp. 283–290, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. C.-H. Lee, D. G. Huntsman, M. C. U. Cheang et al., “Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma,” International Journal of Gynecological Pathology, vol. 24, no. 2, pp. 147–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Malpica, M. T. Deavers, K. Lu et al., “Grading ovarian serous carcinoma using a two-tier system,” American Journal of Surgical Pathology, vol. 28, no. 4, pp. 496–504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Malpica, M. T. Deavers, C. Tomos et al., “Inter-observer and intra-observer variability of a two-tier system for grading ovarian serous carcinoma,” The American Journal of Surgical Pathology, vol. 31, pp. 1203–1208, 2007. View at Google Scholar
  33. D. M. Gershenson, C. C. Sun, K. H. Lu et al., “Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary,” Obstetrics and Gynecology, vol. 108, no. 2, pp. 361–368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. M. A. Crispens, D. Bodurka, M. Deavers et al., “Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential,” Obstetrics and Gynecology, vol. 99, no. 1, pp. 3–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Singer, I.-M. Shih, A. Truskinovsky, H. Umudum, and R. J. Kurman, “Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor),” International Journal of Gynecological Pathology, vol. 22, no. 1, pp. 37–41, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Singer, R. J. Kurman, H.-W. Chang, S. K. Cho, and I.-M. Shih, “Diverse tumorigenic pathways in ovarian serous carcinoma,” American Journal of Pathology, vol. 160, no. 4, pp. 1223–1228, 2002. View at Google Scholar · View at Scopus
  37. G. Singer, R. Oldt III, Y. Cohen et al., “Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma,” Journal of the National Cancer Institute, vol. 95, no. 6, pp. 484–486, 2003. View at Google Scholar · View at Scopus
  38. M. Pradhan, B. Davidson, C. G. Trope et al., “Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas—an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications,” Virchows Archiv, vol. 454, no. 6, pp. 677–683, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Dehari, R. J. Kurman, S. Logani, and I.-M. Shih, “The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis,” The American Journal of Surgical Pathology, vol. 31, no. 7, pp. 1007–1012, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. S. P. Shah, M. Köbel, J. Senz et al., “Mutation of FOXL2 in granulosa-cell tumors of the ovary,” The New England Journal of Medicine, vol. 360, no. 26, pp. 2719–2729, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Crisponi, M. Deiana, A. Loi et al., “The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome,” Nature Genetics, vol. 27, no. 2, pp. 159–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. E. De Baere, M. J. Dixon, K. W. Small et al., “Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype-phenotype correlation,” Human Molecular Genetics, vol. 10, no. 15, pp. 1591–1600, 2001. View at Google Scholar · View at Scopus
  43. D. Beysen, J. Vandesompele, L. Messiaen et al., “The human FOXL2 mutation database,” Human Mutation, vol. 24, no. 3, pp. 189–193, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Cossu-Rocca, S. Zhang, L. M. Roth et al., “Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis,” Modern Pathology, vol. 19, no. 4, pp. 611–615, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. Q. Tian, H. F. Frierson Jr., G. W. Krystal, and C. A. Moskaluk, “Activating c-kit gene mutations in human germ cell tumors,” American Journal of Pathology, vol. 154, no. 6, pp. 1643–1647, 1999. View at Google Scholar · View at Scopus
  46. K. Pauls, E. Wardelmann, S. Merkelbach-Bruse, R. Büttner, and H. Zhou, “c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study,” Virchows Archiv, vol. 445, no. 6, pp. 651–654, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. C. E. Hoei-Hansen, S. M. Kraggerud, V. M. Abeler et al., “Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers,” Molecular Cancer, vol. 6, article 12, 2007. View at Publisher · View at Google Scholar · View at Scopus